Characterization and Evaluation of a Folic Acid Receptor-Targeted Norcantharidin/Tetrandrine Dual-Drug Loaded Delivery System

The objective of this study was to construct norcantharidin (NCTD)/tetrandrine (Tet) dual-drug loaded lipid nanoparticles (FA-LP@Tet/(MSNs@NCTD)) based on mesoporous silica nanoparticles (MSNs) for controlling drug release and lowering their systemic toxicity. In this study, MSNs were prepared and u...

Full description

Saved in:
Bibliographic Details
Published in:Journal of nanomaterials 2019, Vol.2019 (2019), p.1-15
Main Authors: Li, Fanzhu, Mu, Chaofeng, Ma, Rui, Zhang, Tingting, Liu, Wenhong, Tang, Hongxia, Xiong, Youxiang, Zhu, Zhihong
Format: Article
Language:English
Subjects:
Alcohol
Analytical chemistry
Apoptosis
Biocompatibility
Biomedical materials
Cancer therapies
Chemotherapy
Core-shell structure
Drug delivery systems
Encapsulation
Folic acid
Ligands
Lipids
Liposomes
Liver cancer
Nanomaterials
Nanoparticles
Particle size distribution
Penicillin
Silicon dioxide
Sustained release
Tetrandrine
Toxicity
Tumors
Vitamin B
Zeta potential
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to construct norcantharidin (NCTD)/tetrandrine (Tet) dual-drug loaded lipid nanoparticles (FA-LP@Tet/(MSNs@NCTD)) based on mesoporous silica nanoparticles (MSNs) for controlling drug release and lowering their systemic toxicity. In this study, MSNs were prepared and used for encapsulating anticancer drug NCTD; then MSNs@NCTD and Tet were loaded into liposomes to construct dual-drug loaded lipid nanoparticles with folic acid (FA) as the targeting moiety. The prepared dual-drug loaded lipid nanoparticles with a uniform particle size distribution of 153.17±4.17 nm (PDI 0.191±0.017, zeta potential -20.93±1.75 mV), had a visible core-shell structure under transmission electron microscopy; the encapsulation efficiency of NCTD and Tet was 86.62% and 79.19%, respectively, with obvious in vitro sustained release characteristics. The cellular uptake results suggested that FA modification could enhance intracellular distribution of FA-LP@Tet/(MSNs@NCTD). Furthermore, cell apoptosis assays showed FA-LP@Tet/(MSNs@NCTD) had better antitumor ability via reversing multidrug resistance. Therefore, FA-LP@Tet/(MSNs@NCTD) was a promising drug delivery system for combination cancer therapy.
ISSN:1687-4110
1687-4129
DOI:10.1155/2019/7683791